THE STATES OF LAWIE

DEPARTMENT OF THE AIR FORCE

59TH MEDICAL WING (AETC) LACKLAND AIR FORCE BASE TEXAS

18 MAR 2016

MEMORANDUM FOR SGVT

ATTN: LT COL MICHAEL R DAVIS

FROM: 59 MDW/SGVU

SUBJECT: Professional Presentation Approval

- 1. Your paper, entitled <u>Hydrogen Sulfide Delays Onset of Acute Rejection in a Porcine VCA Model</u> presented at <u>2016 Society of Military Surgeons</u>, <u>Boston</u>, <u>MA</u>, <u>17-19 March 2016</u> with MDWI 41-108, and has been assigned local file #16136.
- 2. Pertinent biographic information (name of author(s), title, etc.) has been entered into our computer file. Please advise us (by phone or mail) that your presentation was given. At that time, we will need the date (month, day and year) along with the location of your presentation. It is important to update this information so that we can provide quality support for you, your department, and the Medical Center commander. This information is used to document the scholarly activities of our professional staff and students, which is an essential component of Wilford Hall Ambulatory Surgical Center (WHASC) internship and residency programs.
- 3. Please know that if you are a Graduate Health Sciences Education student and your department has told you they cannot fund your publication, the 59th Clinical Research Division may pay for your basic journal publishing charges (to include costs for tables and black and white photos). We cannot pay for reprints. If you are 59 MDW staff member, we can forward your request for funds to the designated wing POC.
- 4. Congratulations, and thank you for your efforts and time. Your contributions are vital to the medical mission. We look forward to assisting you in your future publication/presentation efforts.


LINDA STEEL-GOODWIN, Col, USAF, BSC

Linda Steel-Goodwin

Director, Clinical Investigations & Research Support

PROCESSING OF PROFES	SSIONAL MEDICAL	RESEARCH/TECHNICAL	PUBLICATION	NSIPPI	ESENTATIONS
1. TO CLINICAL RESEARCH 2. FROM: (Author's Namo, Rank, Grad	do, Offico Symboli			4. PROTOCOL NUMBER:
Michael R	Davis, O-6, Lt Col, 59.V	1DW ST	X YES	ON [Navy 15-09
5. PROTOCOL TITLE: (NOTE: For each ne	w retease of medical resea of review and approval.)	erch or technical information as a	publication/prese	ntalion, a	new 59 MDW Form 3039
Vascularized Composite Allotransplants	or reason and approver.				
6. TITLE OF MATERIAL TO BE PUBLISHED	OR PRESENTED:				
Hydrogen Sulfide Delays Onset of Acut	e Rejection in a Porcine	VCA Model			
7. FUNDING RECEIVED FOR THIS STUDY					
8. DO YOU NEED FUNDING SUPPORT FO		SES: YES NO			
9. IS THIS MATERIAL CLASSIFIED?					
10. IS THIS MATERIAL SUBJECT TO ANY I AND DEVELOPMENT AGREEMENT (CRAD. YES NO NOTE: If the answer is YE	S then attach a copy of the	e Agrooment to the Publications:	CTUDE DOCOCE	コママ ロリンしょ	TO ACCOUNT CYAA
11. MATERIAL IS FOR: DOMESTIC RE	LEASE FOREIGN RE	LEASE			
CHECK APPROPRIATE BOX OR BOXE 11a. PUBLICATION/JOURNAL (LIST In	tended publication/journal.	THIS REQUEST. ATTACH COR	Y OF MATERIAL	. 10 BE P	UBLISHED/PRESENTED.
			2		
11b. PUBLISHED ABSTRACT (List int	ended journal.)				
11c. POSTER (To be demonstrated at	meeting: name of meeting.	, city, state, and date of mueting.)		
11d. PLATFORM PRESENTATION (A	chellan Incituaione: pama	-f			
2016 Society of Military Surgeons.	Boston MA 17-16	or meesing, state, and date of me	Hing.)		
11e. OTHER (Describe: name of moeti	ng, city, state, and date of	meeting.)			
12. EXPECTED DATE WHEN YOU WILL NE NOTE: All publications/presentations are	ED THE CRD TO SUBMIT	YOUR CLEARED PRESENTAT	FION/PUBLICATION	ON TO DT	ic
DATE			Octaci (Dilo).		
March 18, 2016					1
13. 59 MOW PRIMARY POINT OF CONTACT	(Last Name, First Name,	M.I., email)		14. DUTY	PHONE/PAGER NUMBER
Corpus, Raul S raul.s.corpus.etr@mail.n			- 1	210.539.	
15. AUTHORSHIP AND CO-AUTHOR(S) LIS	in the order they will appe	ear in the manuscript,			
LAST NAME, FIRST NAME AND M.I. a. Prirrary/Corresponding Author	GRADE/RANK	SQLADRON/GROUP/OFF	ICE SYMBOL	INST	TUTICK (If not 59 MDW)
Fries Charles A	0-4	59MDW ST			
b. Lawson Shari D	VOI.	59MDW ST			
c. Wang Lin C	0-3	59MDW ST	** * *****		
d. Villamarin Carole Y	0-3	59MDW ST			
e. Gorantla Vijay	VOI.	59MDW ST			
t. Davis Michael R	O-5	59MDW ST			
I CERTIFY ANY HUMAN OR ANIMAL RESEA 219, AFMAN 40-401_IP, AND 59 MDWI 41-10 ACCURATE MANUSCRIPT FOR PUBLICATI	8. I HAVÉ READ THE FIN ON AND/OR PRESENTAT	VAL VERSION OF THE ATTACH TON.	IED MATERIAL A	ND CERT	RDANCE WITH 32 CFR IFY THAT IT IS AN
18. AUTHOR'S PRINTED NAME, RANK, GR	∕DE	17. AUTHOR'S SIGNAT	TURE		18. DATE
Charles A Fries, O-4	た	* CTI			15 MAR 2016
19. APPROVING AUTHORITY'S PRINTED N		20. APPROVING ANTH	ORITY'S SIGNA	TURE	21. DATE
Michael R. Davis, O-5, Director RESTO			1//		ISMAR ZOLL
59 MDW FORM 3039, 20160218 Prescribed by 59 MDW 41-108		CURRENTLY NAMESE VAN BE'	nageo 4	-	Page 2 of 3 Pages

PROCESSING OF PROFESSIONAL MEDICAL RESE	ARCH/TECHNICAL PUBLICATIONS/PRE	SENTATIONS
1st ENDORSEMENT (59 MDW/SGVU Use Only) TO: Clinical Research Division 22. DATE RECEIVED		
59 MDW/CRD Contact 292-7141 for email instructions.	23. ASSIGNED PROCESSING REQUEST FILE N	UMBER
24. DATE REVIEWED		
THE POST OF THE PO	25. DATE FORWARDED TO 502 ISG/JAC	
26. AUTHOR CONTACTED FOR RECOMMENDED OR NECESSARY CHANGE	GES NO TYES If yes give gate	□ N/A
27. COMMENTS APPROVED DISAPPROVED	Д о С. то тупун и	
28. PRINTED NAME, RANKIGRADE, TITLE OF REVIEWER	29. REVIEWER SIGNATURE	30. DATE
Linda D. Harris, GS-14 Chief, Ops Br	Lender Harro	16 Mar 16
2nd ENDORSEMENT (502 ISG/JAC Use Only)	TO CHO HOCKET	107 001.0
31. DATE RECEIVED	32. DATE FORWARDED TO 59 MDW/PA	
33 COMMENTS XX APPROVED (In compliance with security and policy re	land in the state of the state	
Slide presentation includes the disclaimer require		
There are no ethics issues with making this presen	ntation at the 2016 Society for Milita	ry
surgeons meeting.		
	17	
34. PRINTED NAME, RANKIGRADE, TITLE OF REVIEWER Holly J. Mackey, GS-13	B5, REVIEWER SIGNATURE	36. DATE
	Jaley hally	16 Mar 2016
3rd ENDORSEMENT (59 MDW/PA Uso Only) 37. DATE RECEIVED	38, DATE FORWARDED TO 56 MDWSGVU	
17 March 2016	18 March 2016	
39 COMMENTS PROVED (In compliance with security and policy re	eview directives 1 DISAPPROVED	
40. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER	41. REVIEWER SIGNATURE	42, DATE
Christopher Carwile, TSgt/E-6, NCOIC, PA	CARMLE.CHRISTOPHER Institute of the control of the	18 March 2016
4th ENDORSEMENT (59 MDW/SGVU Uso Only)		
43. DATE RECEIVED	NOR AUTHOR NOTIFIED BY PHONE OF APPROVAL S NO COULD NOT BE REACHED L	OR DISAPPROVAL EFT MESSAGE
45. COMMENTS APPROVED DISAPPROVED		
as considera [] without [] provinces		
		40 faats
46. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER	47 REVIEWER SIGNATURE	48. DATE
		1





Disclaimer

The opinions or assertions contained herein are the private views of the author and are not to be construed as official or as reflecting the views of the Department of Defense. The experiments reported herein were conducted according to the principles set forth in the National Institute of Health Publication No. 80-23, Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act of 1966, as amended



Introduction










Surviving soldiers from battelfield injuries are presenting with more complex wound patterns in the extremities and face.

The demand for an advanced method of reconstruction, such as Vascularized composite allotransplantation (VCA), is increasing.



Introduction







Vascularized composite allograft

Free tissue transfer eg, latissimus dorsi flap

Regional flaps eg, posterior interosseous

Local flap eg, rotational/transposition

Skin graft

Secondary closure

Primary closure



Current limitations to vascularized composite allotransplantation (VCA)

- Requires systemic immunosuppression
- Skin is a primary target for rejection
- Limited donor pool
- Few indications
- Shorter period for ischemia time



Ischemia-reperfusion injury (IRI)

- Exacerbation of cellular/tissue injury after an ischemic insult with reestablishment of blood flow
- Generation of oxidative stress
- Microvascular obstruction/thrombosis
- Neutrophil activation
- Complement activation
- Release of anaphylotoxins
- associated with increased rates and severity of acute rejection Increasing severity of IRI at time of transplant in solid organs

Effects of Ischemia and Reperfusion Injury on Long-Term Graft Function

L.R. Requião-Moura, M. de Souza Durão, E.J. Tonato, A.C. Carvalho Matos, K.S. Ozaki, N.O.S. Câmara, and A. Pacheco-Silva



Hydrogen Sulfide





Eric Black Stone, Mike Morrison, Mark B. Roth

Science 22 Apr 2005: Vol. 308, Issue 5721, pp. 518

DOI: 10.1126/science.1108581

- Reversibly reduce the metabolic rate of mice exposed to 80 ppm of hydrogen sulfide
- Core temperature reduced as much as 11 degrees
- Metabolic rate as judged by carbon dioxide production and oxygen consumption dropped 10-fold
- Animals in this state for 6 hours and they recover completely





Role of H₂S in Large Animals

Porcine organ transplant model:

BJS

CINDON A MINE

Hydrogen sulphide ameliorates ischaemia-reperfusion injury in an experimental model of non-heart-beating donor kidney transplantation

S. A. Hosgood and M. L. Nicholson

D 4. 4.

In porcine composite flap model:


TRANSPLANTATION SURGERY AND RESEARCH

Hydrogen Sulfide Mitigates Reperfusion Injury in a Porcine Model of Vascularized Composite Autotransplantation

Carole Y. Villamaria, MD,*† C. Anton Fries, MA, MRCS,‡ Jerry R. Spencer, BS,† Mark Roth, MD,§ and Michael R. Davis, MD, FACS†



Allotransplantation




































Methods

- Single swine leukocyte antigen (SLA) mismatched recipients
- Two groups of 8 animals
- Group 1 flaps received no additional treatment before transplantation
- Group 2 flaps received ex-vivo intra-arterial infusion with H₂S solution before transplantation
- Post-operative period
- 4-mm punch biopsy every 1-3 days for 14 days
- Blinded histologic examination using Banff working classification



Results



Grade 4



Grade 0




Results

	Grade 1 (time in days to acute rejection)	Grade 4 (time in days to acute rejection)
	Mean: 6.4	Mean: 10.5
Controls	SD: 0.52	SD: 2.6
	Mean: 8.9	
H,S treated	SD: 2.3	Mean: >14 days
	p-value= 0.0095	



Results

14 day Rejection by Treatment and Grade



Days to Rejection



Conclusions

- consistent animal model for studying VCA rejection Swine gracilis myocutaneous flap is a reliable and
- H₂S may play a role in mitigating onset of acute rejection in porcine VCA model in the absence of immunosuppression
- Potential use for graft preservation strategies in a clinical setting that may require prolonged ischemic periods





Future research directions

- Repeat applications of H₂S and H₂Se in limb preservation for Nonhuman primates (NHP)
- Combination of local immunomodulatory methods, like drug-eluting microparticles or drug-releasing hydrogels
- Application to swine forelimb allotransplantation model





Thank You





References

- 1. Kosashvili, Y.H., et al. Influence of personal armor on distribution of entry wounds: lessons learned from urban warfare fatalities. J Trauma, 2005; 58(6): 5.
 - 2. Rich, N.M., et al. Acute arterial injuries in Vietnam: 1,000 cases. J Trauma, 1970; 10(5): 359-69.
 - 3. Fox, C.J., Starnes, B.W. Vascular Surgery on the Modern Battlefield. Surg Clin N Am, 2007; 87: 19.
 - 4. Gawande, A. Casualties of war--military care for the wounded from Iraq and Afghanistan. N Engl J Med, 2004 Dec 9; 351(24): 2471-5.
- vascularized composite tissue transplantation. Journal of Surgical Research, 2012; 5. Villamaria, C.Y., et al. Microvascular porcine model for the optimization of 178(1): 452–459.
- 6. Requião-Moura, L.R., et al. Effects of ischemia and reperfusion injury on long-term graft function. Transplant Proc. 2011 Jan-Feb;43(1):70-3.
 - 7. Zdichavsky, M., et al. Scoring of skin rejection in swine composite tissue allograft model. Journal of Surgical Research, 1999; 85 (1) 1-8.
 - 8. Blackstone, E., et al. H₂S induces a suspended animation-like state in mice. Science. 2005 Apr 22;308(5721):518.
- 9. Villamaria, C.Y., et al. Hydrogen sulfide mitigates reperfusion injury in a porcine model of vascularized composite autotransplantation. Ann Plast Surg. 2014 May;72(5):594-8.